Billion-dollar autoimmune drug deal a ‘dream come true’ for Calgary researcher

With autoimmune diseases, the body’s own tissues are mistaken for harmful invaders and attacked

Dr. Pere Santamaria, a professor in the Department of Microbiology, Immunology and Infectious Diseases, and member of the university’s Snyder Institute for Chronic Diseases, poses in this undated handout photo. Parvis Therapeudics, the company Santamaria founded, and California-based company Genetech have reached a billion-dollar deal to develop a potential treatment for celiac disease, irritable bowel syndrome and other autoimmune diseases. THE CANADIAN PRESS/HO - University of Calgary, Riley Brandt

A University of Calgary researcher says he’s hopeful a deal worth up to $1 billion between his drug company and a U.S. biotechnology firm could one day lead to autoimmune disease treatments that don’t make patients more vulnerable to infections or cancer.

“It’s kind of a dream come true that I can play a role in this process and realize something that might perhaps help a lot of people,” said Pere Santamaria, founder of Parvus Therapeutics and a professor at the university’s Cumming School of Medicine.

Parvus announced a working and licensing agreement Thursday with California-based Genentech to develop, manufacture and commercialize a class of drugs known as Navacims to potentially treat celiac, autoimmune liver and inflammatory bowel diseases.

Parvus is to get an upfront payment from Genentech and further payments as certain milestones are reached. The companies are not disclosing precisely how the funds are to be broken down or over what time period. Parvus is also eligible to get royalty payments on sales that result from the deal.

READ MORE: Legalization sparks boom in field of marijuana research

The immune system is meant to protect the body from bacteria, viruses and cancer. But in people with autoimmune diseases, the body’s own tissues are mistaken for harmful invaders and attacked.

Current treatments work by suppressing the immune system as a whole, which makes patients less able to fight off infections and cancer.

Navacims, discovered by Santamaria and his team in 2004, use nanoparticles to switch off autoimmune attacks in a way that doesn’t compromise the body’s overall disease-fighting abilities.

Santamaria said the treatments have been tested extensively in mice with promising results. The deal with Genentech will go toward clinical trials in humans. Parvus will be responsible for initial small-scale tests. Genentech will take on subsequent studies in larger groups and, if successful, the regulatory work needed to bring the drug to market.

The companies aren’t disclosing when the trials will be done, but Santamaria said time is of the essence.

“It’ll take some time, but resources will be brought to bear so that this can be accelerated as fast as we can to get these drugs to patients in need.”

Parvus teamed up with another drug firm, Novartis, in 2017 to develop Navacims as a potential treatment for Type 1 diabetes.

Santamaria said bringing Navacims to market without the resources and know-how from larger partners would be inconceivable.

“It’s been a tough, long haul with a lot of challenges and hurdles in many aspects.”

University of Calgary president Ed McCauley said the big-ticket investment affirms how important it is to invest in fundamental research.

“It’s incredible,” he said. “The discoveries we are making are actually being mobilized to help society.”

Lauren Krugel, The Canadian Press

Like us on Facebook and follow us on Twitter

Just Posted

Learning the intricate ‘ins and outs’ of TaeKwon-do

Popular form of self-defense extends back to ancient times

Local archers off to international competition in Nashville

Deacon Barclay, Katlyne Glasier and Taylor Knudtson landed in the top 24 of NASP Canadian archers recently

Stettler youngster Jake Rock in urgent need of a liver transplant

A GoFundMe page has also been set up to help with medical expenses

Subdivision & Development Appeal Board issues Paradise Shores decision, supports County

SDAB determined the developer’s application was incomplete

Local artist captures vivid images via watercolour

Woody McGibbon continues to explore boundless possibilities via watercolour

10 facts about Father’s Day

Did you know that the special day for dads was first celebrated in 1910?

No business case for Trans Mountain expansion, says former environment minister

Cabinet is expected to announce its decision on the expansion of the Alberta-to-B.C. pipeline by Tuesday

Alberta Mountie found not guilty of dangerous driving causing pedestrian’s death

RCMP Const. Michelle Phillips also found not guilty of dangerous driving causing bodily harm

Three Albertans land ‘monster’ sturgeon in B.C.’s Fraser River

For angler who landed the exceptionally large sturgeon it was an ‘incredible dream come true’

Toronto Raptors and their diverse team celebrated worldwide

Team is made up of players from the U.S., Canada, Cameroon, the Republic of Congo, and Spain

Further murder charge laid after alleged targeted hits in two Alberta cities

Jimmy Truong, who is 27, has been charged with first-degree murder in the shooting of Louie Angelo Mojica

Pot edibles, topicals and extracts to hit shelves no earlier than mid-December: Ottawa

Health Canada wrapped its public consultation on the draft rules for cannabis products in February

We the North: Delirious fans celebrate as Raptors win NBA title

Supporters from all over Canada cheer Toronto’s triumph

Excited, anxious fans prepare for Raptors to play in Game 6 of the NBA Finals

The Raptors currently lead the Warriors 3-2 in the best-of-seven series

Most Read